Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the detection of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The ...

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Dendritic cells (DCs), tissue-resident as well ... Some of these Treg populations are antigen-specific (i.e., their T-cell receptor is specific for pancreatic β-cell-derived antigens).

LMU researchers have shown that a particular type of immune cell acts more flexibly than ... As the researchers demonstrate, dendritic cells that are marked by expression of the transcription ...

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.